A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma; Comparison of (1) VMCP/VBAP to VAD or VMCPP/VBAPP for Induction; (2) Alpha-2b Interferon or No Therapy for Maintenance; and 3) Alpha-2b Interferon + Dexamethasone for Incomplete or Non-Responders; and (4) VAD Plus Verapamil For Incomplete or Non-Responders on VAD

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials

BGM Durie;J Jacobson;B Barlogie;J Crowley Journal of Clinical Oncology 22(10):1857-1863

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

JL Jacobson;MA Hussein;B Barlogie;BGM Durie;JJ Crowley British Journal of Haematology 122:441-450

Partitioning and peeling for constructing prognostic groups

M LeBlanc;J Jacobson;J Crowley Statistical Methods in Medical Research 11:247-274

Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience

J Crowley;J Jacobson;R Alexanian Seminars in Hematology 38(3):203-208

Long term follow-up on SWOG 8624, addressing the role of glucocorticoid dose intensity for remission induction, interferon for maintenance in responders, and dexamethasone + interferon for primary treatment failures

S Salmon;T Grogan;B Barlogie;J Crowley Blood 94(10)Suppl.1:315a(#1410)part_1_of_2

Some exploratory tools for survival analysis.

J Crowley;M LeBlanc;J Jacobson;SE Salmon In Lecture Notes In Statistics :199-229

In reply

SE Salmon;JJ Crowley Journal of Clinical Oncology 13(4):1046

Standard VAD (SWOG-8624) versus total therapy (TT) with 2 autotransplants (AT) for untreated multiple myeloma (MM).

J Crowley;S Jagannath;S Salmon;DH Vesole;G Tricot;B Barlogie ASCO 13:410(#1401)

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study

SE Salmon;JJ Crowley;TM Grogan;P Finley;RP Pugh;B Barlogie Journal of Clinical Oncology 12(11):2405-2414

P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy.

TM Grogan;CM Spier;SE Salmon;M Matzner;JA Rybski;RS Weinstein;RJ Scheper;WS Dalton Blood 81(2):490-495

Quantitative PCR analysis of MDR1 mRNA in patients with multiple myeloma.

BW Futscher;LL Blake;TM Grogan;WS Dalton AACR 33:467(#2792)

Impact of glucocorticoids (GC) and interferon (IFN) on outcome in multiple myeloma.

SE Salmon;J Crowley ASCO 11:316(#1069)

Alpha interferon for remission maintenance: Preliminary report on the Southwest Oncology Group study.

SE Salmon;J Beckord;RP Pugh;B Barlogie;J Crowley Seminars in Oncology 18(5):33-36